You are viewing the site in preview mode
Skip to main content
| |
Intervention group n = 31 (%)
|
Non‐intervention group n = 39 (%)
|
P-value
|
|---|
|
Age
|
70
|
67
|
0.578
|
|
Range
|
51-86
|
28-88
| |
|
Gender
| | |
1.000
|
|
Male
|
27(87.1)
|
35(89.7)
| |
|
Female
|
4(12.9)
|
4(10.3)
| |
|
ECOG PS
| | |
0.645
|
|
0
|
17(54.8)
|
17(43.6)
| |
|
1
|
12(38.7)
|
19(48.7)
| |
|
2
|
2(6.45)
|
3(7.7)
| |
|
Diagnosis
| | |
0.001*
|
|
HCC
|
31(100)
|
27(69.2)
| |
|
RCC
|
-
|
12(30.8)
| |
|
Child-Pugh classification
| | |
0.233
|
|
A
|
29(93.5)
|
22(81.5)
| |
|
B
|
2(6.5)
|
5(18.5)
| |
|
Previous therapy
| | | |
|
HCC
| | |
0.186
|
|
None
|
7(22.6)
|
2(7.4)
| |
|
TACE
|
20(64.5)
|
22(81.5)
| |
|
HAIC
|
10(32.3)
|
3(11.1)
| |
|
RFA
|
10(32.3)
|
13(48.1)
| |
|
TAI
|
1(3.2)
|
1(3.7)
| |
|
Surgery
|
8(25.8)
|
3(11.1)
| |
|
Molecular-targeted therapy
|
2(6.5)
|
-
| |
|
RCC
| | |
0.001*
|
|
None
| |
3(25.0)
| |
|
RFA
|
-
|
1(8.3)
| |
|
Interferon, Interleukin
|
-
|
5(41.7)
| |
|
Surgery
|
-
|
7(58.3)
| |
|
Molecular-targeted therapy
|
-
|
4(33.3)
| |
|
Metastatic site
| | | |
|
HCC
| | |
0.672
|
|
Lung
|
9(29.0)
|
4(14.8)
| |
|
Lymph node
|
9(29.0)
|
3(11.1)
| |
|
Bone
|
3(9.7)
|
1(3.7)
| |
|
Other
|
4(12.9)
|
4(14.8)
| |
|
RCC
| | |
0.001*
|
|
Lung
|
-
|
5(41.7)
| |
|
Lymph node
|
-
|
4(33.3)
| |
|
Bone
|
-
|
4(33.3)
| |
|
Liver
|
-
|
3(25.0)
| |
|
Other
|
-
|
6(50.0)
| |
- *P < 0.05.
-
Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; TACE: transarterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy; RFA: radiofrequency ablation; TAI: transcatheter arterial infusion.
